Understanding Alychlo's Notification to Fagron
Fagron recently received a significant notification regarding major shareholdings, specifically focusing on Alychlo NV. This communication aligns with the Belgian law concerning the disclosure of investor shareholding changes. The announcement underscores the importance of transparency in the operations of publicly listed companies.
Key Details of the Notification
On 14 July, Fagron was informed by Alychlo that they had crossed a notable threshold regarding their shareholding. Alychlo's shareholding fell below 3% due to the disposal of voting securities or voting rights previously held. This specific change took effect following a transaction that took place on 25 July of the preceding year.
The Figures Behind the Announcement
As of 25 July, Alychlo NV possessed a total of 2,139,886 voting rights. Additionally, Marc Coucke, a parent undertaking within the context of the notification, also held a minor share of 7,047 voting rights. When examined against the total amount of voting rights at that time—73,228,904—Alychlo NV and Coucke collectively accounted for 2.93% of the overall voting rights.
Further Insights into Fagron's Operations
Fagron is a prominent player in the pharmaceutical compounding sector, committed to enhancing personalized medicine across a wide array of healthcare environments. Operating in over 30 countries, Fagron places significant emphasis on delivering tailored medication solutions to hospitals, pharmacies, and clinics.
Corporate Structure and Management
The company, headquartered in Nazareth, Belgium, is officially listed on both the Euronext Brussels and Euronext Amsterdam exchanges under the ticker symbol 'FAGR'. The operational activities of Fagron are coordinated by Fagron BV, a Dutch entity based in Rotterdam, which is pivotal in the execution and management of the company’s extensive service offerings.
Communication and Investor Relations
For stakeholders and potential investors, Ignacio Artola serves as Fagron's Global Investor Relations Leader. Those interested in further inquiries can reach out directly through their official communication channels. Fagron is dedicated to maintaining an open dialogue with their investors, ensuring that they are constantly informed about changes and developments that impact their investment decisions.
Commitment to Transparency
Fagron values openness and transparency with its shareholders and the public. The recent notification from Alychlo NV exemplifies the active oversight of shareholding changes that is critical for maintaining trust in the corporate governance landscape. This commitment to transparency helps fortify Fagron’s reputation as a reliable entity in the pharmaceutical industry.
Frequently Asked Questions
What was the nature of the notification received from Alychlo?
The notification indicated that Alychlo NV's shareholding in Fagron crossed below the 3% threshold due to a reduction in their voting rights.
When did the shareholding change occur?
The change in Alychlo's shareholding took effect on 25 July of the previous year, which prompted the notification.
What percentage of voting rights do Alychlo and Marc Coucke hold now?
Together, Alychlo NV and Marc Coucke hold about 2.93% of the total voting rights as of 25 July.
Who can I contact for more information about Fagron?
Ignacio Artola, Fagron's Global Investor Relations Leader, can be contacted for further inquiries regarding the company's operations and investor relations.
Where is Fagron primarily based?
Fagron is based in Nazareth, Belgium, with operational management conducted by Fagron BV in Rotterdam, Netherlands.
